Yiyuan Huanda is a tumor cell immunotherapy developer, focusing on the development of adoptive immune cell products for the treatment of various solid tumors. Synthetic method, novel and efficient tumor-infiltrating T cell expansion scheme in vitro, and cell therapy drug development pipeline with excellent efficacy based on novel third-generation chimeric costimulatory receptors. Recently completed Pre-A round of financing, this round of financing was exclusively invested by Shanghai Biomedical Fund. The funds raised in this round will be used to support the company’s establishment of T cell production functions in Shanghai, the development of the microcircular DNA pilot production process, and the promotion of preclinical research and IIT clinical research of key pipelines in China and the United States, as well as the clinical application of new drugs in China and the United States.
This article is reproduced from: https://www.itjuzi.com/investevent/13275934
This site is for inclusion only, and the copyright belongs to the original author.